I have been under Dr Verter's care for a couple years after a torn retina. He and his team in Westport have been rockstars! Kudos to all!!! 👏👏👏👏
Neovascularization of the Disc (NVD): A Guide for Patients
Understanding Neovascularization of the Disc
NVD is a defining sign of proliferative diabetic retinopathy, the advanced stage of diabetic eye disease. Knowing how and why these abnormal vessels form helps explain why early detection and timely care make such a meaningful difference.
The optic disc is a small, circular area at the back of your eye where the optic nerve enters the retina. In NVD, new blood vessels grow at or within a short distance of this structure. These vessels are not healthy or normal. They are thin, weak, and prone to breaking open and bleeding inside the eye.
NVD is the hallmark finding that separates proliferative diabetic retinopathy from earlier, nonproliferative stages of the disease. When a retina specialist identifies NVD, it signals that diabetic eye disease has progressed significantly and that prompt treatment is needed to reduce the risk of severe vision loss.
Diabetes gradually damages the small blood vessels that nourish the retina over time. As these vessels close off, large areas of the retina lose their blood supply. This oxygen-deprived retinal tissue is called ischemic retina, with ischemic meaning deprived of adequate blood flow. In response, the retina releases a protein called vascular endothelial growth factor, or VEGF. VEGF signals the body to grow new blood vessels in an attempt to restore oxygen delivery to the retina.
The problem is that these new vessels are structurally abnormal. They emerge as fine, fragile tufts on the surface of the retina or the optic nerve head and tend to grow along the back surface of the vitreous, the clear gel that fills the center of the eye. Because they are so fragile, they can rupture and cause a vitreous hemorrhage, meaning bleeding into the vitreous cavity, which can cloud or block vision suddenly.
Not every case of NVD carries the same level of danger, but certain findings are classified as high-risk proliferative diabetic retinopathy. These are situations where the likelihood of serious vision loss without treatment is especially elevated. High-risk features include:
- NVD covering more than one quarter of the optic disc area
- Any amount of NVD combined with vitreous or preretinal hemorrhage, meaning bleeding in front of the retina or into the vitreous
- Neovascularization in other areas of the retina, called NVE, covering more than half the disc area combined with hemorrhage
Research has found that without intervention, nearly one in four eyes with high-risk proliferative diabetic retinopathy may experience severe vision loss within two years, with that risk increasing further over time. Early treatment significantly improves the odds of maintaining useful vision.
Who Is at Risk for NVD
NVD develops as a result of long-standing diabetic eye disease that has not been caught or treated early enough. Several factors influence how quickly diabetic retinopathy can advance to the proliferative stage.
The longer a person has lived with diabetes, the greater the risk of developing diabetic retinopathy and eventually NVD. Research has consistently found that after 20 years with diabetes, nearly all people with type 1 diabetes and a large proportion of those with type 2 diabetes show some degree of retinopathy. Millions of people in the United States are currently affected by diabetic retinopathy, with a meaningful portion having changes severe enough to threaten their vision. Both type 1 and type 2 diabetes can lead to proliferative diabetic retinopathy, though the timeline differs from person to person.
Uncontrolled blood glucose is one of the most significant drivers of diabetic retinopathy progression. A measure called HbA1c, which reflects average blood sugar levels over roughly two to three months, is closely linked to both the development and the worsening of NVD. The higher the HbA1c over time, the greater the risk. High blood pressure further damages fragile retinal blood vessels and can accelerate disease progression. Keeping both blood sugar and blood pressure within recommended ranges is one of the most important steps a person with diabetes can take to protect their eyes.
Several additional factors can raise the risk of advancing to high-risk proliferative diabetic retinopathy. Your retina specialist will consider these as part of a thorough evaluation:
- Diabetic neuropathy, meaning nerve damage caused by diabetes
- Kidney disease related to diabetes
- Elevated triglyceride levels in the blood
- Lower hematocrit, which is a measure of the proportion of red blood cells in the blood
- Younger age at the time of diabetes diagnosis
- Visible changes in the diameter of retinal blood vessels that can be observed during a dilated eye exam
Understanding your personal risk profile allows your care team to recommend the right monitoring schedule and to intervene early when signs of progression appear.
Signs, Symptoms, and Warning Signs
NVD is sometimes described as a visually silent condition because it can develop and worsen without causing any noticeable change in vision. Understanding what may signal a problem, and when to act urgently, can be critical to protecting your sight.
One of the most challenging aspects of NVD is that a person can have significant abnormal blood vessel growth at the optic disc while still seeing clearly. There may be no pain, no blurred vision, and no obvious warning that anything is wrong. This is why regular dilated eye exams are so important for everyone living with diabetes. Waiting for symptoms to appear before seeking care can allow the condition to reach a stage where preventing vision loss becomes far more difficult.
When symptoms do develop, they typically mean that a complication such as bleeding has already taken place. You may notice:
- A sudden increase in floaters, which are dark spots, strings, or cobweb-like shapes drifting across your vision
- Blurred or hazy vision
- Dark or shadowy areas in your field of view
- A noticeable decrease in vision in one or both eyes
- Eye discomfort or pain in some cases, though this is less common
Small collections of blood called preretinal hemorrhages can also form in the space between the vitreous and the retina. These are important warning signs that abnormal vessels are active and at risk of causing more significant bleeding episodes.
Some symptoms require immediate attention and should not be waited on. Contact a retina specialist or go to an emergency room right away if you experience any of the following:
- A sudden flood or shower of new floaters
- Flashes of light in your vision
- A dark curtain, shadow, or veil spreading across any part of your vision
- Sudden, significant vision loss in one or both eyes
These symptoms may indicate a vitreous hemorrhage or a retinal detachment. Both are sight-threatening emergencies that require urgent evaluation and treatment to prevent permanent vision damage.
How We Diagnose NVD
Detecting NVD as early as possible gives us the best opportunity to protect your vision. We use a combination of clinical examination and specialized imaging to evaluate your retina and monitor disease activity over time.
The primary method for detecting NVD is a comprehensive dilated eye exam. During this exam, we use drops to widen your pupils so that a retina specialist can see the retina and optic disc directly. NVD appears as clusters of fine, abnormal blood vessels growing on or near the surface of the optic disc. A skilled retina specialist can often identify these vessels before they cause any symptoms, which is one of the most important reasons to maintain regular exams if you have diabetes.
Fluorescein angiography is a specialized imaging test that gives us detailed information about blood flow in the retina. A small amount of fluorescent dye is injected into a vein in your arm, and a camera captures rapid-sequence photographs as the dye travels through the retinal blood vessels. Areas affected by NVD appear brightly lit in these images because the abnormal vessels leak dye. This test helps us determine the location and extent of neovascularization and identify areas of the retina that have been deprived of adequate blood flow.
Optical coherence tomography, or OCT, uses light waves to create detailed cross-sectional images of the retina. It can reveal swelling, fluid accumulation, and structural changes associated with diabetic eye disease. Newer technologies such as wide-field imaging and swept-source OCT angiography (OCT-A) allow us to view a much larger portion of the retina at once and track changes in blood vessel activity over time, often without requiring a dye injection. These tools give us a more complete picture of how your retina is responding to treatment and where additional intervention may be needed.
Treatment Options for NVD
Treatment for NVD focuses on stopping the growth of abnormal blood vessels, preventing bleeding and scar tissue formation, and preserving as much vision as possible. The right approach depends on the severity of your condition, whether complications have occurred, and other individual factors your retina specialist will carefully evaluate.
Anti-VEGF medications work by blocking the protein VEGF (vascular endothelial growth factor) that signals the body to produce abnormal blood vessels. These medications are delivered through an intravitreal injection, meaning they are injected directly into the vitreous cavity of the eye. Anti-VEGF therapy has become a primary treatment option for NVD and proliferative diabetic retinopathy because it can rapidly reduce the size and activity of abnormal blood vessels. Medications commonly used for this purpose include:
- Aflibercept (Eylea), typically given every four to eight weeks after an initial loading phase
- High-dose aflibercept (Eylea HD), an FDA-approved formulation that may allow extended dosing intervals of every eight to sixteen weeks after loading
- Ranibizumab (Lucentis), typically given every four weeks
- Bevacizumab (Avastin), which is FDA-approved for cancer treatment and used off-label in the eye, typically given every four to six weeks
- Faricimab (Vabysmo), a bispecific antibody that targets two pathways involved in abnormal vessel growth, given every four to sixteen weeks depending on individual response
Clinical research has demonstrated that anti-VEGF therapy can perform comparably to laser treatment in managing proliferative diabetic retinopathy in many patients. Some eyes show meaningful regression of abnormal vessels within weeks of beginning treatment. Your retina specialist will recommend the most appropriate medication and schedule based on your individual needs.
Panretinal photocoagulation, commonly called PRP, has been a cornerstone of treatment for proliferative diabetic retinopathy for several decades. During PRP, a laser creates precise burns in the peripheral, or outer, areas of the retina. This reduces the amount of ischemic retinal tissue, which lowers the level of VEGF being produced. With less VEGF driving their growth, abnormal blood vessels tend to shrink and become less active over time.
PRP does not improve vision, but it is highly effective at halting further vision loss. Because it provides durable, long-lasting control of neovascularization, it remains an important part of care for many patients with high-risk proliferative diabetic retinopathy.
In many cases, we use anti-VEGF injections in combination with PRP laser treatment. This approach offers both immediate and sustained benefits. The injection rapidly reduces active neovascularization, while the laser provides longer-term control by lowering the ischemic stimulus that drives vessel growth in the first place.
When serious complications have already occurred, such as a vitreous hemorrhage that does not clear on its own or a tractional retinal detachment (where scar tissue forms and pulls the retina away from the back of the eye), a surgical procedure called vitrectomy may be necessary. During vitrectomy, the vitreous gel is removed from inside the eye so the surgeon can address bleeding and repair retinal damage. Early vitrectomy may improve outcomes in selected cases, particularly when a clear view of the retina is needed or when the retina is at risk of further detachment.
What to Expect During and After Treatment
Knowing what each procedure involves and what recovery looks like can help ease the anxiety that often comes with a new diagnosis. Our team walks you through every step of your care so you feel informed and prepared.
An intravitreal injection is a quick, in-office procedure that typically takes only a few minutes. We use anesthetic drops to numb the eye and carefully clean the area before administering the medication through a very fine needle. Most patients feel pressure rather than sharp pain, though some mild discomfort is normal. You may notice temporary floaters or slight blurriness in the treated eye afterward, which usually resolves within a day or two.
Anti-VEGF treatment for NVD typically involves a series of injections over time. How frequently you receive them depends on how your eye responds. We monitor your progress closely with regular exams and imaging and adjust your treatment schedule as your condition changes.
Panretinal photocoagulation is performed in the office and may be completed over one or more sessions. We use numbing drops and a special contact lens placed gently on your eye to guide the laser precisely. You may see bright flashes of light during the procedure and experience mild discomfort. After PRP, some patients notice a gradual reduction in peripheral (side) vision and night vision. This is a known effect of the treatment and reflects the trade-off between protecting your central vision, which is used for reading, driving, and recognizing faces, and reducing the ischemic retinal tissue that fuels abnormal vessel growth. We discuss these effects with you in advance so you can make a fully informed decision.
NVD and proliferative diabetic retinopathy require long-term monitoring, even after treatment has been working well. Abnormal blood vessels can regrow if the underlying diabetes-related damage continues, particularly when blood sugar control is not optimal. Your retina specialist will schedule follow-up visits based on your individual progress. During active treatment, these appointments may occur every few weeks. Once the condition is stable, they may be spaced out to every few months. Staying consistent with these visits is one of the most important commitments you can make for your eye health.
Protecting Your Vision Long-Term
Managing NVD and proliferative diabetic retinopathy is an ongoing effort that extends well beyond your eye appointments. The choices you make each day about your diabetes management and overall health have a direct impact on the health of your eyes.
Keeping your diabetes under control is the single most important factor in slowing the progression of diabetic retinopathy. Work closely with your primary care doctor or endocrinologist to keep your HbA1c, blood pressure, and cholesterol within recommended ranges. Research consistently shows that better blood sugar control is associated with slower retinopathy progression and a lower risk of complications such as vitreous hemorrhage. Treating your diabetes well is, in a very real sense, also treating your eyes.
In addition to medical treatment, certain everyday habits support your overall health and may help slow retinopathy progression over time:
- Follow a balanced diet designed to support stable blood sugar levels
- Engage in regular physical activity as recommended by your doctor
- Avoid smoking, which worsens damage to blood vessels throughout the body including those in the retina
- Take all prescribed medications consistently, including those for blood pressure, cholesterol, and blood sugar
- Keep all scheduled eye and medical appointments, even when your vision feels unchanged
Small, consistent habits can make a meaningful difference in how your condition progresses over time.
Living with a serious eye condition can be emotionally challenging, and it is entirely normal to feel anxious or uncertain about what lies ahead. Diabetes education programs, vision rehabilitation services, and peer support groups can offer both practical strategies and a sense of community. If vision changes have begun to affect your daily activities, a low vision specialist can recommend assistive devices and techniques to help you maintain as much independence as possible. You do not have to navigate this condition alone, and our team is here to support you beyond the clinical visit.
Frequently Asked Questions
Below are answers to questions we commonly hear from patients and families about NVD and proliferative diabetic retinopathy. If you have a concern not addressed here, our team is glad to help.
Anti-VEGF injections can cause abnormal blood vessels to shrink significantly, and in many cases neovascularization regresses substantially during a course of treatment. However, it is important to understand that diabetic retinopathy is a chronic condition driven by ongoing diabetes-related damage to retinal blood vessels. Treatment controls the abnormal vessel growth and helps prevent vision-threatening complications, but it does not cure the underlying disease. Individual responses vary, and continued monitoring with periodic treatment adjustments is a standard part of long-term care. Your retina specialist will give you the most realistic picture of what improvement is possible based on your specific situation.
Injection frequency is highly individual and typically changes over the course of treatment. Most plans begin with more frequent injections during an initial loading phase, often every four to eight weeks, to bring the neovascularization under control. As your eye responds, your retina specialist may gradually extend the time between injections. Some patients eventually reach a point where fewer visits are needed to maintain stable results, while others require ongoing treatment at consistent intervals to keep abnormal vessels inactive. The schedule is never fixed and will be adjusted based on how your eye responds over time, so open communication with your specialist at each visit is important.
Both approaches are effective, and the better choice depends on your specific circumstances. Anti-VEGF injections tend to act more quickly and may better preserve peripheral visual field, but they require regular ongoing visits. Panretinal photocoagulation provides durable, long-lasting control with fewer follow-up treatments, though it carries the known trade-off of some reduction in peripheral and night vision. Many retina specialists use both in combination, starting with anti-VEGF therapy for rapid control and then applying laser treatment for longer-term stability. Factors such as the severity of your retinopathy, the presence of complications, and your ability to attend regular appointments all play a role in determining which approach is recommended for you.
Without treatment, the fragile abnormal vessels associated with NVD can rupture and cause a vitreous hemorrhage that may severely blur or completely block vision. Over time, scar tissue can form along these vessels and contract, pulling the retina away from the back of the eye in a condition called a tractional retinal detachment. Both complications can result in serious and potentially permanent vision loss. Research has found that a substantial proportion of eyes with high-risk proliferative diabetic retinopathy experience severe vision loss within two years without intervention, with that risk rising further over time. The longer care is delayed, the more complex and limited the treatment options may become.
While there is no way to guarantee prevention entirely, strong control of blood sugar, blood pressure, and cholesterol significantly lowers the risk of developing proliferative diabetic retinopathy. Regular dilated eye exams allow your eye care team to detect early changes before they reach the proliferative stage, and if earlier stages of retinopathy are identified, closer monitoring and timely treatment can interrupt the progression. The combination of consistent diabetes management and routine screening represents the most effective protective approach currently available. Taking both seriously gives your vision the best possible chance over the long term.
We Are Here for Your Retinal Health
At New England Retina Associates, our fellowship-trained vitreoretinal surgeons have deep experience diagnosing and treating NVD and all stages of diabetic retinopathy, and we are committed to providing thorough, compassionate care to every patient we see. Whether you have been referred by your eye doctor or are seeking evaluation on your own, we warmly welcome you to schedule a consultation at any of our offices serving patients throughout Connecticut and the surrounding region.
30 Years of Care & Commitment
